These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20494948)

  • 21. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
    Gotlib V; Khaled S; Lapko I; Mar N; Saif MW
    Anticancer Drugs; 2006 Nov; 17(10):1227-9. PubMed ID: 17075324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
    Luo W; Liao WJ; Ma L; Huang YT; Shi M; Wen Q; Wang XN
    Cancer Immunol Immunother; 2010 Feb; 59(2):247-56. PubMed ID: 19652968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-resectable metastases from colorectal cancers].
    Di Fiore F
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 2):S140-4. PubMed ID: 18468824
    [No Abstract]   [Full Text] [Related]  

  • 25. Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.
    Ozen A; Cicin I; Sezer A; Uzunoglu S; Saynak M; Genchellac H; Karagol H
    J Cancer Res Ther; 2009; 5(2):130-2. PubMed ID: 19542672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
    Venook AP; Blanke CD; Niedzwiecki D; Lenz HJ; Taylor JR; Hollis DR; Sutherland S; Goldberg RM
    Clin Colorectal Cancer; 2005 Nov; 5(4):292-4. PubMed ID: 16356309
    [No Abstract]   [Full Text] [Related]  

  • 27. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
    Abbrederis K; Kremer M; Schuhmacher C
    Chirurg; 2008 Apr; 79(4):351-5. PubMed ID: 17453167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
    Grothey A; Marshall JL
    Oncology (Williston Park); 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8. PubMed ID: 17536342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
    Dranitsaris G; Shah A; Spirovski B; Vincent M
    Clin Colorectal Cancer; 2007 Jan; 6(5):367-73. PubMed ID: 17311702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemotherapy for elderly patients with colorectal cancer].
    Kuboki Y; Mizunuma N
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):380-6. PubMed ID: 17353628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
    Robertson JD; Botwood NA; Rothenberg ML; Schmoll HJ
    Clin Colorectal Cancer; 2009 Jan; 8(1):59-60. PubMed ID: 19203899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
    Grothey E; Chu E
    Clin Colorectal Cancer; 2007 Sep; 6(9):621-4. PubMed ID: 17945033
    [No Abstract]   [Full Text] [Related]  

  • 34. [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
    Zheng H; Chen JZ; Liao WJ; Luo RC
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):689-91. PubMed ID: 16762887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
    BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High incidence of silent venous thromboembolism before treatment in ovarian cancer.
    Satoh T; Oki A; Uno K; Sakurai M; Ochi H; Okada S; Minami R; Matsumoto K; Tanaka YO; Tsunoda H; Homma S; Yoshikawa H
    Br J Cancer; 2007 Oct; 97(8):1053-7. PubMed ID: 17895896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
    Ribero D; Wang H; Donadon M; Zorzi D; Thomas MB; Eng C; Chang DZ; Curley SA; Abdalla EK; Ellis LM; Vauthey JN
    Cancer; 2007 Dec; 110(12):2761-7. PubMed ID: 17960603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line Palliative Chemotherapy for Colorectal Cancer: a Population-based Analysis of Delivery and Outcomes in a Single-payer Health System.
    Wilson BE; Booth CM; Patel S; Berry S; Kong W; Merchant SJ
    Clin Oncol (R Coll Radiol); 2024 Apr; 36(4):211-220. PubMed ID: 38199907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin-related acute myelogenous leukemia.
    Carneiro BA; Kaminer L; Eldibany M; Sreekantaiah C; Kaul K; Locker GY
    Oncologist; 2006 Mar; 11(3):261-2. PubMed ID: 16549810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic therapy for colorectal cancer.
    Meyerhardt JA; Mayer RJ
    N Engl J Med; 2005 Feb; 352(5):476-87. PubMed ID: 15689586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.